{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:25:44Z","timestamp":1648826744833},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"DOI":"10.2146\/ajhp130145","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T19:48:26Z","timestamp":1400183306000},"page":"919-923","source":"Crossref","is-referenced-by-count":5,"title":["Bowel perforation associated with temsirolimus use in a recently irradiated patient"],"prefix":"10.1093","volume":"71","author":[{"given":"Claire M.","family":"Mach","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Houston, and Division of Gynecologic Oncology, Baylor College of Medicine, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anze","family":"Urh","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Baylor College of Medicine."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology and Dan L. Duncan Cancer Center, Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041211013795000_b1-0710919","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0002-9378(12)90910-2","article-title":"Leiomyosarcomas: clinical presentation","volume":"168","author":"Schwartz","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"2019041211013795000_b2-0710919","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Survival epidemiology and end results analysis of 2677 cases of uterine sarcomas, 1989\u2013 1999","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol Oncol"},{"key":"2019041211013795000_b3-0710919","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1245\/s10434-013-2876-y","article-title":"Predictors of survival and recurrence in primary leiomyosarcoma","volume":"20","author":"Gladdy","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2019041211013795000_b4-0710919","first-page":"95","article-title":"Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study","volume":"48","author":"Bodner","year":"2003","journal-title":"J Reprod Med"},{"key":"2019041211013795000_b5-0710919","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2019041211013795000_b6-0710919","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2008.11.027","article-title":"Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study","volume":"112","author":"Hensley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2019041211013795000_b7-0710919","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E","article-title":"A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas","volume":"52","author":"Omura","year":"1983","journal-title":"Cancer"},{"key":"2019041211013795000_b8-0710919","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol Oncol"},{"key":"2019041211013795000_b9-0710919","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7","article-title":"Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)","volume":"55","author":"Muss","year":"1985","journal-title":"Cancer"},{"key":"2019041211013795000_b10-0710919","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/1097-0142(197809)42:3<1152::AID-CNCR2820420319>3.0.CO;2-L","article-title":"Uterine sarcomas: natural history, treatment and prognosis","volume":"42","author":"Salazar","year":"1978","journal-title":"Cancer"},{"key":"2019041211013795000_b11-0710919","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1477-7819-7-38","article-title":"Treatment of early uterine sarcomas: disentangling adjuvant modalities","volume":"7","author":"Zagouri","year":"2009","journal-title":"World J Surg Oncol"},{"key":"2019041211013795000_b12-0710919","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"key":"2019041211013795000_b13-0710919","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2019041211013795000_b14-0710919","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.bjc.6604636","article-title":"mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?","volume":"99","author":"Le Tourneau","year":"2008","journal-title":"Br J Cancer"},{"key":"2019041211013795000_b15-0710919","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"2019041211013795000_b16-0710919","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"2019041211013795000_b17-0710919","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/CAD.0b013e3283442074","article-title":"Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway","volume":"22","author":"Italiano","year":"2011","journal-title":"Anticancer Drugs"},{"key":"2019041211013795000_b18-0710919","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.25928","article-title":"A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)","volume":"117","author":"Okuno","year":"2011","journal-title":"Cancer"},{"key":"2019041211013795000_b19-0710919","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-12-0436","article-title":"Dual targeting of mTOR and aurora-A kinase for the treatment of uterine leiomyosarcoma","volume":"18","author":"Brewer Savannah","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2019041211013795000_b20-0710919","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","article-title":"An expanding role for mTOR in cancer","volume":"11","author":"Guertin","year":"2005","journal-title":"Trends Mol Med"},{"key":"2019041211013795000_b21-0710919","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2019041211013795000_b22-0710919","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1517\/13543784.17.11.1717","article-title":"mTOR inhibitors in the treatment of cancer","volume":"17","author":"Fasolo","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"2019041211013795000_b23-0710919","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019041211013795000_b24-0710919","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2019041211013795000_b25-0710919","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019041211013795000_b26-0710919","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/annonc\/mdg248","article-title":"Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors","volume":"14","author":"Punt","year":"2003","journal-title":"Ann Oncol"},{"key":"2019041211013795000_b27-0710919","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cancers5020418","article-title":"A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma","volume":"5","author":"Verschraegen","year":"2013","journal-title":"Cancers"},{"key":"2019041211013795000_b28-0710919","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharm Ther"},{"key":"2019041211013795000_b29-0710919","volume-title":"Avastin (bevacizumab) package insert","year":"2013"},{"key":"2019041211013795000_b30-0710919","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"2019041211013795000_b31-0710919","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4143\/crt.2008.40.1.33","article-title":"Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin)","volume":"40","author":"Choi","year":"2008","journal-title":"Cancer Res Treat"},{"key":"2019041211013795000_b32-0710919","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.01.038","article-title":"What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?","volume":"105","author":"Han","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2019041211013795000_b33-0710919","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.ajog.2008.08.048","article-title":"Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report","volume":"200","author":"Chereau","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"2019041211013795000_b34-0710919","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"suppl 3","key":"2019041211013795000_b35-0710919","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"key":"2019041211013795000_b36-0710919","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevadizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"2019041211013795000_b37-0710919","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cursur.2006.06.002","article-title":"Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology and management","volume":"65","author":"Heinzerling","year":"2006","journal-title":"Curr Surg"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/11\/919\/28372664\/ajhp0919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:49:36Z","timestamp":1555116576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/11\/919\/5110909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,1]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130145","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,6,1]]},"published":{"date-parts":[[2014,6,1]]}}}